18 results on '"Sun, Qian"'
Search Results
2. Decoding key cell sub-populations and molecular alterations in glioblastoma at recurrence by single-cell analysis.
- Author
-
Wang, Xin, Sun, Qian, Wang, Weiwen, Liu, Baohui, Gu, Ying, and Chen, Liang
- Subjects
- *
AP-1 transcription factor , *BRAIN tumors , *GLIOBLASTOMA multiforme , *GENE regulatory networks , *MYELOID cells - Abstract
Glioblastoma (GBM) is the most frequent malignant brain tumor, the relapse of which is unavoidable following standard treatment. However, the effective treatment for recurrent GBM is lacking, necessitating the understanding of key mechanisms driving tumor recurrence and the identification of new targets for intervention. Here, we integrated single-cell RNA-sequencing data spanning 36 patient-matched primary and recurrent GBM (pGBM and rGBM) specimens, with 6 longitudinal GBM spatial transcriptomics to explore molecular alterations at recurrence, with each cell type characterized in parallel. Genes involved in extracellular matrix (ECM) organization are preferentially enriched in rGBM cells, and MAFK is highlighted as a potential regulator. Notably, we uncover a unique subpopulation of GBM cells that is much less detected in pGBM and highly expresses ECM and mesenchyme related genes, suggesting it may contribute to the molecular transition of rGBM. Further regulatory network analysis reveals that transcription factors, such as NFATC4 and activator protein 1 members, may function as hub regulators. All non-tumor cells alter their specific sets of genes as well and certain subgroups of myeloid cells appear to be physically associated with the mesenchyme-like GBM subpopulation. Altogether, our study provides new insights into the molecular understanding of GBM relapse and candidate targets for rGBM treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Identification and validation of a novel prognostic signature based on mitochondria and oxidative stress related genes for glioblastoma.
- Author
-
Tong, Shiao, Xia, Minqi, Xu, Yang, Sun, Qian, Ye, Liguo, Yuan, Fanen, Wang, Yixuan, Cai, Jiayang, Ye, Zhang, and Tian, Daofeng
- Subjects
MITOCHONDRIA ,GLIOBLASTOMA multiforme ,REACTIVE oxygen species ,GENES ,RECEIVER operating characteristic curves - Abstract
Background: Mitochondria represent a major source of reactive oxygen species (ROS) in cells, and the direct increase in ROS content is the primary cause of oxidative stress, which plays an important role in tumor proliferation, invasion, angiogenesis, and treatment. However, the relationship between mitochondrial oxidative stress-related genes and glioblastoma (GBM) remains unclear. This study aimed to investigate the value of mitochondria and oxidative stress-related genes in the prognosis and therapeutic targets of GBM. Methods: We retrieved mitochondria and oxidative stress-related genes from several public databases. The LASSO regression and Cox analyses were utilized to build a risk model and the ROC curve was used to assess its performance. Then, we analyzed the correlation between the model and immunity and mutation. Furthermore, CCK8 and EdU assays were utilized to verify the proliferative capacity of GBM cells and flow cytometry was used to analyze apoptosis rates. Finally, the JC-1 assay and ATP levels were utilized to detect mitochondrial function, and the intracellular ROS levels were determined using MitoSOX and BODIPY 581/591 C11. Results: 5 mitochondrial oxidative stress-related genes (CTSL, TXNRD2, NUDT1, STOX1, CYP2E1) were screened by differential expression analysis and Cox analysis and incorporated in a risk model which yielded a strong prediction accuracy (AUC value = 0.967). Furthermore, this model was strongly related to immune cell infiltration and mutation status and could identify potential targeted therapeutic drugs for GBM. Finally, we selected NUDT1 for further validation in vitro. The results showed that NUDT1 was elevated in GBM, and knockdown of NUDT1 inhibited the proliferation and induced apoptosis of GBM cells, while knockdown of NUDT1 damaged mitochondrial homeostasis and induced oxidative stress in GBM cells. Conclusion: Our study was the first to propose a prognostic model of mitochondria and oxidative stress-related genes, which provided potential therapeutic strategies for GBM patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. The dual role of p62 in ferroptosis of glioblastoma according to p53 status.
- Author
-
Yuan, Fanen, Sun, Qian, Zhang, Si, Ye, Liguo, Xu, Yang, Deng, Gang, Xu, Zhou, Zhang, Shenqi, Liu, Baohui, and Chen, Qianxue
- Subjects
- *
P53 antioncogene , *P53 protein , *GLUTAMATE transporters , *GLIOBLASTOMA multiforme , *TRANSMISSION electron microscopy , *LIPID analysis , *NUCLEAR factor E2 related factor - Abstract
Background: Ferroptosis plays a key role in human cancer, but its function and mechanism in glioma is not clear. P62/SQSTM1 was reported to inhibit ferroptosis via the activation of NRF2 signaling pathway. In this study we reveal a dual role of p62 in ferroptosis of glioblastoma (GBM) according to p53 status. Method: Lipid peroxidation analysis, transmission electron microscopy (TEM), GSH assay were performed to determine the level of ferroptosis. Western blot and qPCR were obtained to detect the expression of ferroptosis markers. Construction of mutant plasmids, immunoprecipitation, luciferase assay and rescue-experiments were performed to explore the regulatory mechanism. Results: P62 overexpression facilitates ferroptosis and inhibits SLC7A11 expression in p53 mutant GBM, while attenuates ferroptosis and promotes SLC7A11 expression in p53 wild-type GBM. P62 associates with p53 and inhibits its ubiquitination. The p53-NRF2 association and p53-mediated suppression of NRF2 antioxidant activity are diversely regulated by p62 according to p53 status. P53 mutation status is required for the dual regulation of p62 on ferroptosis. In wild-type p53 GBM, the classical p62-mediated NRF2 activation pathway plays a major regulatory role of ferroptosis, leading to increased SLC7A11 expression, resulting in a anti-ferroptosis role. In mutant p53 GBM, stronger interaction of mutant-p53/NRF2 by p62 enhance the inhibitory effect of mutant p53 on NRF2 signaling, which reversing the classical p62-mediated NRF2 activation pathway, together with increased p53's transcriptional suppression on SLC7A11 by p62, leading to a decrease of SLC7A11, resulting in a pro-ferroptosis role. Conclusion: Together, this study shows novel molecular mechanisms of ferroptosis regulated by p62; the mutation status of p53 is an important factor that determines the therapeutic response to p62-mediated ferroptosis-targeted therapies in GBM. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Hsa_circ_0072309 enhances autophagy and TMZ sensitivity in glioblastoma.
- Author
-
Yuan, Fanen, Zhang, Si, Sun, Qian, Ye, Liguo, Xu, Yang, Xu, Zhou, Deng, Gang, Zhang, Shenqi, Liu, Baohui, and Chen, Qianxue
- Subjects
AUTOPHAGY ,GLIOBLASTOMA multiforme ,METHYLGUANINE ,P53 protein ,TRANSMISSION electron microscopy ,CIRCULAR RNA - Abstract
Aims: Circular RNAs have been reported to play key roles in the progression of various cancers, including gliomas. The present study was designed to investigate the role of hsa_circ_0072309 in autophagy and temozolomide (TMZ) sensitivity in glioblastoma (GBM). Methods: The effect of hsa_circ_0072309 on autophagy and TMZ sensitivity were examined by GFP‐RFP‐LC3, transmission electron microscopy(TEM), flow cytometry, Western blot, and immunofluorescence. The mechanism of hsa_circ_0072309 regulating p53 signaling pathway was analyzed using Western blot, IP, and rescue experiments. Results: Low hsa_circ_0072309 expression predicts poor prognosis for glioma patients. The regulation of hsa_circ_0072309 on autophagy and TMZ sensitivity depends on the status of p53. Hsa_circ_0072309 promoted autophagy by p53 signaling pathway and enhanced sensitivity of glioblastoma to temozolomide (TMZ) in p53 wild‐type GBM, but not in p53 mutant GBM. Hsa_circ_0072309 inhibits p53 ubiquitination and increases the stability of p53 protein in the context of p53 wild‐type. MiR‐100 mediates hsa_circ_0072309 regulating p53. P53 inhibitor or autophagy inhibitor could reverse the effect of hsa_circ_0072309 on TMZ sensitivity in p53 wild‐type GBM. Conclusions: This study revealed a function of hsa_circ_0072309 promoting autophagy by p53 signaling pathway and enhancing TMZ sensitivity. These findings demonstrated that hsa_circ_0072309 may be a potential and promising target in designing the treatment strategy for GBM. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Rho family GTPase 1 (RND1), a novel regulator of p53, enhances ferroptosis in glioblastoma.
- Author
-
Sun, Qian, Xu, Yang, Yuan, Fan'en, Qi, Yangzhi, Wang, Yixuan, Chen, Qianxue, and Liu, Baohui
- Subjects
- *
CELL death , *GUANOSINE triphosphatase , *GLIOBLASTOMA multiforme , *METHYLGUANINE , *REACTIVE oxygen species , *TRANSMISSION electron microscopy , *P53 protein - Abstract
Background: Ferroptosis is an iron dependent cell death closely associated with p53 signaling pathway and is aberrantly regulated in glioblastoma (GBM), yet the underlying mechanism needs more exploration. Identifying new factors which regulate p53 and ferroptosis in GBM is essential for treatment. Methods: Glioma cell growth was evaluated by cell viability assays and colony formation assays. Lipid reactive oxygen species (ROS) assays, lipid peroxidation assays, glutathione assays, and transmission electron microscopy were used to assess the degree of cellular lipid peroxidation of GBM. The mechanisms of RND1 in regulation of p53 signaling were analyzed by RT-PCR, western blot, immunostaining, co-immunoprecipitation, ubiquitination assays and luciferase reporter assays. The GBM‐xenografted animal model was constructed and the tumor was captured by an In Vivo Imaging System (IVIS). Results: From the The Cancer Genome Atlas (TCGA) database, we summarized that Rho family GTPase 1 (RND1) expression was downregulated in GBM and predicted a better prognosis of patients with GBM. We observed that RND1 influenced the glioma cell growth in a ferroptosis-dependent manner when GBM cell lines U87 and A172 were treated with Ferrostatin-1 or Erastin. Mechanistically, we found that RND1 interacted with p53 and led to the de-ubiquitination of p53 protein. Furthermore, the overexpression of RND1 promoted the activity of p53-SLC7A11 signaling pathway, therefore inducing the lipid peroxidation and ferroptosis of GBM. Conclusions: We found that RND1, a novel controller of p53 protein and a positive regulator of p53 signaling pathway, enhanced the ferroptosis in GBM. This study may shed light on the understanding of ferroptosis in GBM cells and provide new therapeutic ideas for GBM. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Betulinic acid self-assembled nanoparticles for effective treatment of glioblastoma.
- Author
-
Li, Yong, Wang, Yixuan, Gao, Lun, Tan, Yinqiu, Cai, Jiayang, Ye, Zhang, Chen, Ann T., Xu, Yang, Zhao, Linyao, Tong, Shiao, Sun, Qian, Liu, Baohui, Zhang, Shenqi, Tian, Daofeng, Deng, Gang, Zhou, Jiangbing, and Chen, Qianxue
- Subjects
BETULINIC acid ,BLOOD-brain barrier ,CENTRAL nervous system tumors ,CELL survival ,GLIOBLASTOMA multiforme ,BRAIN tumors ,WESTERN immunoblotting ,EMULSIONS (Pharmacy) - Abstract
Background: Glioblastoma (GBM) is the most common and fatal primary tumor in the central nervous system (CNS). Due to the existence of blood–brain barrier (BBB), most therapeutics cannot efficiently reach tumors in the brain, and as a result, they are unable to be used for effective GBM treatment. Accumulating evidence shows that delivery of therapeutics in form of nanoparticles (NPs) may allow crossing the BBB for effective GBM treatment. Methods: Betulinic acid NPs (BA NPs) were synthesized by the standard emulsion approach and characterized by electron microscopy and dynamic light scattering analysis. The resulting NPs were characterized for their anti-tumor effects by cell viability assay, EdU-DNA synthesis assay, cell cycle assay, mitochondrial membrane potential, and PI-FITC apoptosis assay. Further mechanistic studies were carried out through Western Blot and immunostaining analyses. Finally, we evaluated BA NPs in vivo for their pharmacokinetics and antitumor effects in intracranial xenograft GBM mouse models. Results: BA NPs were successfully prepared and formed into rod shape. BA NPs could significantly suppress glioma cell proliferation, induce apoptosis, and arrest the cell cycle in the G0/G1 phase in vitro. Furthermore, BA NPs downregulated the Akt/NFκB-p65 signaling pathway in a concentration dependent manner. We found that the observed anti-tumor effect of BA NPs was dependent on the function of CB1/CB2 receptors. Moreover, in the intracranial GBM xenograft mouse models, BA NPs could effectively cross the BBB and greatly prolong the survival time of the mice. Conclusions: We successfully synthesized BA NPs, which could cross the BBB and demonstrated a strong anti-tumor effect. Therefore, BA NPs may potentially be used for effective treatment of GBM. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. HSP27 protects against ferroptosis of glioblastoma cells.
- Author
-
Yuan, Fanen, Sun, Qian, Zhang, Si, Ye, Liguo, Xu, Yang, Xu, Zhou, Liu, Baohui, Zhang, Shenqi, and Chen, Qianxue
- Subjects
GLIOBLASTOMA multiforme ,GLIOMAS ,CELL death - Abstract
Ferroptosis, as an new form of non-apoptotic regulated cell death, plays an important role in human cancers. Although it is reported that HSP27 is an novel regulator of ferroptosis in cancer, it remains unknown how HSP27 affects ferroptosis in glioma. In this study, we examined the effect of HSP27 on the ferroptosis of glioblasotma. HSP27 overexpression protects glioblastoma cells from erastin-induced ferroptosis while HSP27 depletion promotes erastin-induced ferroptosis of glioblastoma. Notably, HSP27 phosphorylation is required for the protective function of HSP27 in erastin-induced ferroptosis. Overall, our study reveal novel molecular mechanisms of ferroptosis in glioma and also identify HSP27 as a negative regulator of ferroptosis and a potential target for the treatment of glioma. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. DYRK1A activates NFATC1 to increase glioblastoma migration.
- Author
-
Liu, Heng, Sun, Qian, Chen, Shuai, Chen, Long, Jia, Wenming, Zhao, Juan, and Sun, Xiulian
- Subjects
- *
GLIOBLASTOMA multiforme , *METHYLGUANINE , *SURVIVAL rate , *GLIOMAS , *POLYPEPTIDES , *PATHOGENESIS - Abstract
Glioblastoma (GBM) is the most aggressive glioma, and is prone to develop resistance to chemotherapy and radiotherapy; hence, patients with glioblastoma have a high recurrence rate and a low 1‐year survival rate. In addition, the pathogenesis of glioblastoma is complex and largely unknown, and the available treatments are limited. Here, we uncovered a fundamental role of DYRK1A in regulating NFATC1 in GBMs. We found that DYRK1A was highly expressed in glioma and glioblastoma cells, and its expression was positively correlated with that of NFATC1. Moreover, inhibition of DYRK1A promoted NFATC1 degradation in GBM cells and sharply reduced the transactivation of NFATC1, not only by decreasing the expression of NFATC1‐targeted genes, but also by reducing the luciferase activity, and vice versa. However, DYRK1A had the opposite effect on NFATC2. Most importantly, our data suggest that DYRK1A inhibition reduces glioblastoma migration. Polypeptides derived from the DYRK1A‐targeted motif of NFATC1, by competitively blocking DYRK1A kinase activity on NFATC1, clearly destabilized NFATC1 protein and impaired glioblastoma migration. We propose that the recovery of NFATC1 stability is a key oncogenic event in a large proportion of gliomas, and pharmacological inhibition of DYRK1A by polypeptides could represent a promising therapeutic intervention for GBM. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. The New PI3K/mTOR Inhibitor GNE-477 Inhibits the Malignant Behavior of Human Glioblastoma Cells.
- Author
-
Wang, Yixuan, Shen, Heng, Sun, Qian, Zhao, Linyao, Liu, Hao, Ye, Liguo, Xu, Yang, Cai, Jiayang, Li, Yuntao, Gao, Lun, Tan, Yinqiu, Liu, Baohui, and Chen, Qianxue
- Subjects
CENTRAL nervous system tumors ,GLIOBLASTOMA multiforme ,DISEASE relapse - Abstract
The most common primary central nervous system tumor in adults is glioblastoma multiforme (GBM). The high invasiveness of GBM cells is an important factor leading to inevitable tumor recurrence and a poor prognosis of patients. GNE-477, a novel PI3K/mTOR inhibitor, has been reported to exert antiproliferative effects on other cancer cells. However, researchers have not clearly determined whether GNE-477 produces antitumor effects on GBM. In the present study, GNE-477 significantly inhibited the proliferation, migration and invasion of U87 and U251 cells. In addition, GNE-477 also induced apoptosis of GBM cells, arresting the cell cycle in G0/G1 phase. More importantly, GNE-477 also reduced the levels of AKT and mTOR phosphorylation in the AKT/mTOR signaling pathway in a concentration-dependent manner. An increase in AKT activity induced by SC79 rescued the GNE-477-mediated inhibition of GBM cell proliferation and apoptosis. The antitumor effects of GNE-477 and the regulatory effects on related molecules were further confirmed in vivo using a nude mouse intracranial xenograft model. In conclusion, our study indicated that GNE-477 exerted significant antitumor effects on GBM cells in vitro and in vivo by downregulating the AKT/mTOR pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. AKT Inhibitor SC66 Inhibits Proliferation and Induces Apoptosis in Human Glioblastoma Through Down-Regulating AKT/β-Catenin Pathway.
- Author
-
Gao, Lun, Liu, Junhui, Xu, Pengfei, Deng, Gang, Liu, Baohui, Yuan, Fanen, Tan, Yinqiu, Sun, Qian, Xu, Yang, Zhang, Huikai, Qi, Yangzhi, Han, Shoumeng, Yang, Kun, Geng, Rongxin, Jiang, Hongxiang, and Chen, Qianxue
- Subjects
GLIOBLASTOMA multiforme ,CELL migration ,CELL cycle ,APOPTOSIS ,CANCER cells ,EPITHELIAL-mesenchymal transition ,CELL migration inhibition - Abstract
Glioblastoma multiforme (GBM) is the most common intracranial malignancy in adults with the highest degree of malignancy and mortality. Due to its nature of diffuse invasiveness and high migration, GBM lacks an effective treatment strategy and is associated with poor prognosis. SC66 is a novel AKT inhibitor that has been reported to exert antiproliferative activity in many types of cancer cells. However, it remains unclear whether SC66 has antitumor effects in GBM. In this study, we found SC66 obviously suppressed U87 and U251 cell proliferation and EMT- mediated cell migration and invasion. Moreover, SC66 induced GBM cells apoptosis and arrested cell cycle in G0/G1 phase. Furthermore, SC66 also downregulated AKT signaling pathway in a concentration dependent manner. We also found the level of β-catenin nuclear translocation was prominently downregulated after SC66 treatment. Meanwhile, TCF/LEF luciferase report assay indicated that the activity of TCF/LEF was remarkably suppressed. Elevating β-catenin activity by using IM12 rescued SC66 inhibition‐mediated GBM cell proliferation and metastasis. In addition, SC66 showed significantly suppressed the tumorigenicity compared to the control group in the xenograft mouse model. In conclusion, our study demonstrated that SC66 exerts prominently antitumor efficiency in GBM cells in vivo and in vitro by downregulated AKT/β-catenin pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
12. Esterase-responsive and size-optimized prodrug nanoparticles for effective intracranial drug delivery and glioblastoma treatment.
- Author
-
Ye, Zhang, Gao, Lun, Cai, Jiayang, Wang, Yixuan, Li, Yong, Tong, Shiao, Yan, Tengfeng, Sun, Qian, Qi, Yangzhi, Xu, Yang, Jiang, Hongxiang, Zhang, Si, Zhao, Linyao, Zhang, Shenqi, and Chen, Qianxue
- Subjects
PRODRUGS ,GLIOBLASTOMA multiforme ,TUMOR growth ,BLOOD-brain barrier ,CHEMICAL synthesis ,NANOPARTICLES - Abstract
Glioblastoma multiforme (GBM) is the intracranial malignancy with the highest rates of morbidity and mortality. Chemotherapy is often ineffective against GBM due to the presence of the blood–brain barrier (BBB); however, the application of nanotechnology is expected to overcome this limitation. Poly(lactic-co-glycolic acid) (PLGA) is a degradable and nontoxic functional polymer with good biocompatibility that is widely used in the pharmaceutical industry. Previous studies have shown that the ability of PLGA nanoparticles (NPs) to penetrate the BBB is largely determined by their size; however, determination of the optimal PLGA NP size requires further research. Here, we report a tandutinib-based prodrug (proTan), which responds to the GBM microenvironment, that was combined with NPs to overcome the BBB. AMD3100-PLGA NPs loaded with proTan inhibited tumor growth and effectively prolonged the survival of tumor-bearing mice. Schematic representations of (A) Chemical synthesis of proTan, (B) Synthesis of AMD-PLGA/proTan and (C) Application for drug delivery to GBM. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. The RNA-binding protein CSTF2 regulates BAD to inhibit apoptosis in glioblastoma.
- Author
-
Xu, Yang, Yuan, Fanen, Sun, Qian, Zhao, Linyao, Hong, Yu, Tong, Shiao, Qi, Yangzhi, Ye, Liguo, Hu, Ping, Ye, Zhang, Zhang, Si, Liu, Baohui, and Chen, Qianxue
- Subjects
- *
RNA-binding proteins , *GLIOBLASTOMA multiforme , *GENE expression , *CANCER cells , *APOPTOSIS - Abstract
RNA-binding proteins (RBP) regulate several aspects of co- and post-transcriptional gene expression in cancer cells. CSTF2 is involved in the expression of many cellular mRNAs and involved in the 3′-end cleavage and polyadenylation of pre-mRNAs to terminate transcription. However, the role of CSTF2 in human glioblastoma (GBM) and the underlying mechanisms remain unclear. In the present study, CSTF2 was found to be upregulated in GBM, and its high expression predicted poor prognosis. Knockdown CSTF2 induced GBM cell apoptosis both in vitro and in vivo. Specific mechanism studies showed that CSTF2 unstabilized the mRNA of the BAD protein by shortening its 3' UTR. Additionally, an increase in the expression level of CSTF2 decreased the expression level of BAD. In conclusion, CSTF2 binds to the mRNA of the BAD protein to shorten its 3'UTR, which negatively affects the BAD mediated apoptosis and promotes GBM cell survival. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Hsa_circ_0072309 inhibits proliferation and invasion of glioblastoma.
- Author
-
Yuan, Fanen, Sun, Qian, Xu, Yang, Zhang, Huikai, Deng, Gang, Yang, Jian, Zhang, Shenqi, Liu, Junhui, Liu, Baohui, and Chen, Qianxue
- Subjects
- *
GLIOBLASTOMA multiforme , *CELL proliferation - Abstract
Increasing literature reported that circRNAs play vital roles in the occurrence and progression of GBM and regulate GBM cell proliferation, metastases, and chemosensitivity. However, the expression pattern and function of circRNAs in GBM still need further studies. In our work, hsa_circ_0072309 was remarkably downregulated in GBM. Hsa_circ_0072309 inhibits proliferation and invasion of glioblastoma and affects cytoskeletal of GBM cells. Moreover, we found that the function of hsa_circ_0,072,309 in GBM was associated with HSP27, which was reported to be an important regulator of cell proliferation, invasion and cytoskeletal. Our study provides a novel view of hsa_circ_0072309 in GBM cell proliferation and invasion, indicating that hsa_circ_0072309 may act as a potential therapeutic target for GBM comprehensive treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Notch intracellular domain regulates glioblastoma proliferation through the Notch1 signaling pathway.
- Author
-
Wang, Yixuan, Sun, Qian, Geng, Rongxin, Liu, Hao, Yuan, Fan'en, Xu, Yang, Qi, Yangzhi, Jiang, Hongxiang, Chen, Qianxue, and Liu, Baohui
- Subjects
- *
GLIOBLASTOMA multiforme , *CORTISONE , *CELL proliferation , *IMMUNOSTAINING , *CELL differentiation - Abstract
Notch intracellular domain (NICD), also known as the activated form of Notch1 is closely associated with cell differentiation and tumor invasion. However, the role of NICD in glioblastoma (GBM) proliferation and the underlying regulatory mechanism remains unclear. The present study aimed to investigate the expression of NICD and Notch1 downstream gene HES5 in human GBM and normal brain samples and to further detect the effect of NICD on human GBM cell proliferation. For this purpose, western blotting and immunohistochemical staining were performed to analyze the expression of NICD in human GBM tissues, while western blotting and reverse-transcription quantitative PCR experiments were used to analyze the expression of Hes5 in human GBM tissues. A Flag-NICD vector was used to overexpress NICD in U87 cells and compound E and small interfering (si) Notch1 were used to downregulate NICD. Cellular proliferation curves were generated and BrdU assays performed to evaluate the proliferation of U87 cells. The results demonstrated that compared with normal brain tissues, the level of NICD protein in human GBM tissues was upregulated and the protein and mRNA levels of Hes5 were also upregulated in GBM tissues indicating that the Notch1 signaling pathway is activated in GBM. Overexpression of NICD promoted the proliferation of U87 cells in vitro while downregulation of NICD by treatment with compound E or siNotch1 suppressed the proliferation of U87 cells in vitro. In conclusion, NICD was upregulated in human GBM and NICD promoted GBM proliferation via the Notch1 signaling pathway. NICD may be a potential diagnostic marker and therapeutic target for GBM treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. Small GTPase RHOE/RND3, a new critical regulator of NF‐κB signalling in glioblastoma multiforme?
- Author
-
Sun, Qian, Dong, Huimin, Li, Yuntao, Yuan, Fan'en, Xu, Yang, Mao, Shanping, Xiong, Xiaoxing, Chen, Qianxue, and Liu, Baohui
- Subjects
- *
GLIOBLASTOMA multiforme , *GUANOSINE triphosphatase , *PROTEIN expression , *PROTEIN binding , *PROTEASE inhibitors , *UBIQUITINATION - Abstract
Objectives: Abnormal activation of NF‐κB signalling is a major mechanism of apoptosis resistance in glioblastoma multiforme (GBM). Therefore, better understanding of the regulation of NF‐κB signalling has a significant impact for GBM therapy. Here, we uncovered a critical role of the small GTPase RND3 in regulating the p65 subunit of NF‐κB and NF‐κB signalling in GBM. Materials and methods: Human GBM samples, GBM cells and a human orthotopic GBM‐xenografted animal model were used. The mechanisms of RND3 in regulation of NF‐κB signalling and GBM cell apoptosis were examined by luciferase assay, quantitative PCR, immunostaining, immunoblotting, immunofluorescence, coimmunoprecipitation, TUNEL staining, JC‐1 analysis and flow cytometry. Results: Overexpression of RND3 led to reduced p65 activity in GBM‐cultured cells and a GBM animal model, indicating that the NF‐κB pathway is negatively regulated by RND3 in GBM. Mechanistically, we found that RND3 bound p65 and promoted p65 ubiquitination, leading to decreased p65 protein levels. Furthermore, RND3 enhanced cleaved caspase 3 levels and promoted apoptosis in GBM cells, and RND3 expression was positively correlated with cleaved caspase 3 and IL‐8 in human GBM samples. The effect of RND3 on promoting apoptosis disappeared when p65 ubiquitination was blocked by protease inhibitor carfilzomib or upon co‐expression of ectopic p65. Conclusions: RND3 binds p65 protein and promotes its ubiquitination, resulting in reduced p65 protein expression and inhibition of NF‐κB signalling to induce GBM cell apoptosis. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.
- Author
-
Han, Yu, Yan, Lin-Feng, Wang, Xi-Bin, Sun, Ying-Zhi, Zhang, Xin, Liu, Zhi-Cheng, Nan, Hai-Yan, Hu, Yu-Chuan, Yang, Yang, Zhang, Jin, Yu, Ying, Sun, Qian, Tian, Qiang, Hu, Bo, Xiao, Gang, Wang, Wen, and Cui, Guang-Bin
- Subjects
GLIOBLASTOMA multiforme ,DNA methyltransferases ,O6-Methylguanine-DNA Methyltransferase ,CEREBRAL circulation ,MAGNETIC resonance imaging ,BRAIN tumor diagnosis ,PROTEIN metabolism ,DNA metabolism ,ENZYME metabolism ,BRAIN tumors ,COMPARATIVE studies ,DNA ,ENZYMES ,GENES ,GLIOMAS ,RESEARCH methodology ,MEDICAL cooperation ,PROTEINS ,RESEARCH ,RESEARCH funding ,EVALUATION research ,RETROSPECTIVE studies ,RECEIVER operating characteristic curves ,DNA methylation ,DIAGNOSIS - Abstract
Background: The methylation status of oxygen 6-methylguanine-DNA methyltransferase (MGMT) promoter has been associated with treatment response in glioblastoma(GBM). Using pre-operative MRI techniques to predict MGMT promoter methylation status remains inconclusive. In this study, we investigated the value of features from structural and advanced imagings in predicting the methylation of MGMT promoter in primary glioblastoma patients.Methods: Ninety-two pathologically confirmed primary glioblastoma patients underwent preoperative structural MR imagings and the efficacy of structural image features were qualitatively analyzed using Fisher's exact test. In addition, 77 of the 92 patients underwent additional advanced MRI scans including diffusion-weighted (DWI) and 3-diminsional pseudo-continuous arterial spin labeling (3D pCASL) imaging. Apparent diffusion coefficient (ADC) and relative cerebral blood flow (rCBF) values within the manually drawn region-of-interest (ROI) were calculated and compared using independent sample t test for their efficacies in predicting MGMT promoter methylation. Receiver operating characteristic curve (ROC) analysis was used to investigate the predicting efficacy with the area under the curve (AUC) and cross validations. Multiple-variable logistic regression model was employed to evaluate the predicting performance of multiple variables.Results: MGMT promoter methylation was associated with tumor location and necrosis (P < 0.05). Significantly increased ADC value (P < 0.001) and decreased rCBF (P < 0.001) were associated with MGMT promoter methylation in primary glioblastoma. The ADC achieved the better predicting efficacy than rCBF (ADC: AUC, 0.860; sensitivity, 81.1%; specificity, 82.5%; vs rCBF: AUC, 0.835; sensitivity, 75.0%; specificity, 78.4%; P = 0.032). The combination of tumor location, necrosis, ADC and rCBF resulted in the highest AUC of 0.914.Conclusion: ADC and rCBF are promising imaging biomarkers in clinical routine to predict the MGMT promoter methylation in primary glioblastoma patients. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
18. BCAS3 accelerates glioblastoma tumorigenesis by restraining the P53/GADD45α signaling pathway.
- Author
-
Wang, Yixuan, Li, Yuntao, Sun, Qian, Yuan, Fan'en, Xu, Yang, Tong, Shiao, Li, Yong, Yi, Shangfeng, Yan, Tengfeng, Chen, Qianxue, and Liu, Baohui
- Subjects
- *
CELLULAR signal transduction , *CELL cycle regulation , *GLIOBLASTOMA multiforme , *CELL division , *CELL proliferation , *CELL cycle - Abstract
As in many other cancers, highly malignant proliferation and disordered cell division play irreplaceable roles in the exceedingly easy recurrence and complex progression of glioblastoma multiforme (GBM); however, mechanistic studies of the numerous regulators involved in this process are still insufficiently thorough. The role of BCAS3 has been studied in other cancers, but its role in GBM is unclear. Here, our goal was to investigate the expression pattern of BCAS3 in GBM and its potential mechanism of action. Using TCGA database and human GBM samples, we found that BCAS3 expression was up-regulated in GBM, and its high expression predicted poor prognosis. To further investigate the relationship between BCAS3 and GBM characteristics, we up-regulated and down-regulated BCAS3 expression in GBM to detect its effect on cell proliferation and cell cycle. At the same time, we established U87 cells stably overexpressing BCAS3 and generated an intracranial xenograft model to investigate the Potential role of BCAS3 in vivo. Finally, based on in vitro cell experiments and in vivo GBM xenograft models, we observed that BCAS3 significantly regulates GBM cell proliferation and cell cycle and that this regulation is associated with p53/GADD45α Signaling pathway. Taken together, our findings suggest that BCAS3 is inextricably linked to the progression of GBM and that targeting BCAS3 may have therapeutic effects in GBM patients. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.